GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development

The Guardian (UK)IndependentCenter6 hr. ago

GlaxoSmithKline (GSK), a major British pharmaceutical company, is implementing a £1.9 billion cost-cutting strategy that includes significant job reductions. As part of this initiative, GSK plans to invest £400 million in the UK's life sciences sector over the next three years, focusing on establishing a new research and development center in Cambridge. This move involves relocating over 1,000 scientists to the Cambridge facility and closing its current R&D site in Stevenage by 2029, while upgrading facilities in nearby Ware. GSK's CEO, Luke Miels, emphasized that this investment aims to speed up drug development and integrate the company deeper into the UK's life sciences ecosystem. The decision has been positively received by local leaders, including Andy Burnham, who called it a 'vote of confidence' in British business. This follows similar investments by GSK's competitor, AstraZeneca, which recently reversed its earlier decision to pause large-scale projects in the UK.

Bias read (Center): The article presents a balanced overview of GSK's strategic decisions, highlighting both the cost-cutting measures and the investment in UK life sciences. There is no evident bias toward either supporting or criticizing the company's actions, and the information provided is factual and neutral.

The IndependentIndependentCenter7 hr. ago

Pharmaceutical company GlaxoSmithKline (GSK) has announced plans to relocate its main research and development headquarters from Stevenage, Hertfordshire, to Cambridge, England, as part of a £400 million investment strategy. The move aims to streamline operations and cut costs by £1.9 billion over three years, which will be reinvested into R&D and other initiatives. The new Cambridge facility will house over 1,000 scientists and is expected to be completed by 2029. Some employees from Stevenage will be relocated to GSK's upgraded site in Ware, while others may lose their positions. The decision comes amid ongoing restructuring efforts, including previous job cuts in the U.S. and U.K., and is intended to support future growth and offset losses from the expiration of patents on key drugs like dolutegravir.

Bias read (Center): The article focuses on corporate restructuring and investment decisions by a pharmaceutical company, which falls under business news rather than politics. There is no indication of political bias in the framing, sourcing, or emphasis of the content. The report presents factual information about GSKs